3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Unknown
1
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
2
Thoracic
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Ovarian Neoplasms
1
Neoplasms, Squamous Cell
1
Melanoma
1
Esophageal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
Paclitaxel
69
Carboplatin
66
Cisplatin
36
pembrolizumab
34
Gemcitabine
24
liposomal doxorubicin
23
Cyclophosphamide
23
Topotecan
22
Bevacizumab
20
Taxes
14
Docetaxel
13
niraparib
12
Nivolumab
12
olaparib
10
fludarabine
10
Doxorubicin
9
Surveys and Questionnaires
8
Radiotherapy
8
Oxaliplatin
8
aldesleukin
7
Filgrastim
7
rucaparib
6
oregovomab
6
fludarabine phosphate
6
durvalumab
6
avelumab
6
Interleukin-2
6
Hyperthermic Intraperitoneal Chemotherapy
6
Fluorodeoxyglucose F18
6
Cytoreduction Surgical Procedures
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
High-Intensity Focused Ultrasound Ablation
×
Gynecologic
×
Clear all
NCT04116320
2025-07-14
AM-003
University of Virginia
Phase 1
Terminated
5 enrolled